Effect of Recombinant Human EPO on the Postoperative Neurologic Outcome in Pediatric Moyamoya Patients

Exclusion Criteria

• •Hypersensitivity or contraindication to rHuEPO
• •History of Unstable hypertension, Hypertensive encephalopathy, Thrombosis
• •Primary intracerebral hemorrhage (ICH), Subarachnoid hemorrhage (SAH), Arterio-venous malformation (AVM), Cerebral aneurysm, or cerebral neoplasm
• •History of seizure
• •Hemoglobin \>16 mg/dl
• •Prolonged PT (PT \> 15.5 seconds, PT INR \> 1.2) or Prolonged aPTT (\> 40 seconds)
• •Thrombocytopenia (platelet count \< 100,000/microL), Thrombocytosis (platelet count \> 400,000/microL), Neutropenia (absolute neutrophil count (ANC) \< 1500/microL)
• •Abnormal kidney function (Creatinine\> 2.0 mg/dl, History of dialysis)
• •Abnormal hepatic function (aspartate transaminase\> 80 unit/L, alanine aminotransferase\> 80 unit/L)